XT
AVBP icon

XTX Topco’s ArriVent BioPharma AVBP Stock Holding History

XTX Topco’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Sell
62,332
-670
-1% -$19.8K 0.03% 1040
2026
Q1 		$1.45M Buy
63,002
+36,749
+140% +$830K 0.03% 1113
2025
Q4 		$528K Buy
+26,253
New +$546K 0.01% 1543

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's AVBP Position: Q2 2026 in Review

XTX Topco reduced its ArriVent BioPharma (AVBP) stake by 1.1% in Q2 2026, selling an estimated $19.8K and leaving 62,332 shares worth $2.17M. The position accounts for 0.03% of the portfolio, ranked #1040.

XTX Topco first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • XTX Topco held 62,332 shares of ArriVent BioPharma worth $2.17M as of Q2 2026.
  • XTX Topco sold 670 ArriVent BioPharma shares in Q2 2026, an estimated $19.8K.
  • ArriVent BioPharma made up 0.03% of XTX Topco's portfolio in Q2 2026, its #1040 holding.
  • XTX Topco first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.